@article{d2421d7cc6a944b498ac4bec5ed6ccd3,
title = "Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy",
abstract = "Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different clinical trials.",
keywords = "Hepatitis D, New treatment approaches, Surrogate marker, Treatment endpoints",
author = "{Hepatitis Delta International Network (HDIN)} and Cihan Yurdaydin and Zaigham Abbas and Maria Buti and Markus Cornberg and Rafael Esteban and Ohad Etzion and Gane, {Edward J.} and Gish, {Robert G.} and Glenn, {Jeffrey S.} and Saeed Hamid and Theo Heller and Christopher Koh and Pietro Lampertico and Yoav Lurie and Michael Manns and Raymundo Parana and Mario Rizzetto and Stephan Urban and Heiner Wedemeyer and A. Wranke and {Pinheiro Borzacov}, {L. M.} and C. Lobato and S. Hamid and E. Ceausu and Dalekos, {G. N.} and A. Turcanu and Niro, {G. A.} and F. Lubna and M. Abbas and P. Ingiliz and P. Ferenci and T. Vanwolleghem and T. Hayden and N. Dashdorj and A. Motoc and S. Hardtke",
note = "Publisher Copyright: {\textcopyright} 2018",
year = "2019",
month = may,
day = "1",
doi = "10.1016/j.jhep.2018.12.022",
language = "English",
volume = "70",
pages = "1008--1015",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "5",
}
